Company intelligence / Profile preview

ZymoGenetics

Seattle, Washington, USAsec.gov ↗

Ownership: Private
Development stage: Other

Overview

Pegylated interferon-lambda showed promise as a next-generation therapy for hepatitis C with potentially improved safety over existing interferons. Recothrom was approved and marketed as a recombinant thrombin product. Other legacy assets included outlicensed insulins and coagulation factors now commercialized by partners.

Therapeutic areas: HematologyEndocrinologyInfectious Diseases
Modalities: Recombinant proteinProteinBiologicCytokine
Industry: Biotech

Partnerships

Historical partnership with Novo NordiskCollaboration with Bristol Myers Squibb

Beyond the preview

Go deeper on ZymoGenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZymoGenetics.

Explore the full profile